FR3119986B1 - Composition émulsion eau dans huile et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements - Google Patents

Composition émulsion eau dans huile et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements Download PDF

Info

Publication number
FR3119986B1
FR3119986B1 FR2101621A FR2101621A FR3119986B1 FR 3119986 B1 FR3119986 B1 FR 3119986B1 FR 2101621 A FR2101621 A FR 2101621A FR 2101621 A FR2101621 A FR 2101621A FR 3119986 B1 FR3119986 B1 FR 3119986B1
Authority
FR
France
Prior art keywords
water
oil emulsion
treatment
prevention
radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2101621A
Other languages
English (en)
Other versions
FR3119986A1 (fr
Inventor
Gareth Winckle
Philippe Andres
Janusz Czernielewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tarian Pharma SAS
Original Assignee
Tarian Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR2101621A priority Critical patent/FR3119986B1/fr
Application filed by Tarian Pharma SAS filed Critical Tarian Pharma SAS
Priority to US18/264,289 priority patent/US20240100045A1/en
Priority to JP2023574755A priority patent/JP2024507011A/ja
Priority to KR1020237031786A priority patent/KR20230147155A/ko
Priority to AU2022222303A priority patent/AU2022222303A1/en
Priority to PCT/EP2022/054044 priority patent/WO2022175434A2/fr
Priority to CA3204646A priority patent/CA3204646A1/fr
Priority to CN202280015431.8A priority patent/CN116887811A/zh
Priority to EP22706816.0A priority patent/EP4294364A2/fr
Publication of FR3119986A1 publication Critical patent/FR3119986A1/fr
Priority to ZA2023/06742A priority patent/ZA202306742B/en
Application granted granted Critical
Publication of FR3119986B1 publication Critical patent/FR3119986B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

L’invention concerne une composition sous une forme adaptée à une administration par voie topique à base d’eau comprenant un vasoconstricteur. L’invention se caractérise en ce qu’elle se présente sous forme d’émulsion eau dans huile comportant des cristaux liquides et en ce que la composition comprend un vasoconstricteur choisi parmi la brimonidine ou ses sels, dans une phase solvantée comprenant : - du polyéthylène glycol en combinaison avec du propylène glycol ; - un copolymère Polyvinylpyrrolidone/Vinyl Acetate (comme agent filmogène hydrophile ; - de la glycérine ; - un émulsifiant choisi parmi l’association PEG-75 stearate et glycéryl monostéarate et l’association polyoxyethylène-20 sorbitan monostearate (polysorbate-60) et alcool cétostéarylique ; - un acide oléique ou un alcool oléique, préférentiellement un alcool oléique ; - et une phase huileuse adaptée à l’obtention d’une émulsion eau dans huile comportant des cristaux liquides. L’invention concerne également la composition selon l’invention pour son utilisation en tant que médicament, plus particulièrement dans la prévention et/ou le traitement de dermatite résultant d’un rayonnement notamment dans le cadre d’un traitement par radiothérapie. Figure 6
FR2101621A 2021-02-19 2021-02-19 Composition émulsion eau dans huile et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements Active FR3119986B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR2101621A FR3119986B1 (fr) 2021-02-19 2021-02-19 Composition émulsion eau dans huile et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements
EP22706816.0A EP4294364A2 (fr) 2021-02-19 2022-02-18 Composition emulsion et ses utilisations dans la prevention et/ou le traitement des dommages cutanes causes par les rayonnements
KR1020237031786A KR20230147155A (ko) 2021-02-19 2022-02-18 방사선으로 인한 피부 손상의 예방 및/또는 치료에 있어서의 에멀젼 조성물 및 이의 용도
AU2022222303A AU2022222303A1 (en) 2021-02-19 2022-02-18 Emulsion composition and uses thereof in the prevention and/or treatment of skin damage caused by radiation
PCT/EP2022/054044 WO2022175434A2 (fr) 2021-02-19 2022-02-18 Composition emulsion et ses utilisations dans la prevention et/ou le traitement des dommages cutanes causes par les rayonnements
CA3204646A CA3204646A1 (fr) 2021-02-19 2022-02-18 Composition emulsion et ses utilisations dans la prevention et/ou le traitement des dommages cutanes causes par les rayonnements
US18/264,289 US20240100045A1 (en) 2021-02-19 2022-02-18 Emulsion composition and uses thereof in the prevention and/or treatment of skin damage caused by radiation
JP2023574755A JP2024507011A (ja) 2021-02-19 2022-02-18 エマルション組成物、ならびに放射線によって引き起こされる皮膚損傷の予防および／または処置におけるその使用
CN202280015431.8A CN116887811A (zh) 2021-02-19 2022-02-18 乳剂组合物及其在预防和/或治疗由辐射引起的皮肤损伤中的用途
ZA2023/06742A ZA202306742B (en) 2021-02-19 2023-06-30 Emulsion composition and uses thereof in the prevention and/or treatment of skin damage caused by radiation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2101621A FR3119986B1 (fr) 2021-02-19 2021-02-19 Composition émulsion eau dans huile et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements
FR2101621 2021-02-19

Publications (2)

Publication Number Publication Date
FR3119986A1 FR3119986A1 (fr) 2022-08-26
FR3119986B1 true FR3119986B1 (fr) 2024-02-16

Family

ID=75108601

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2101621A Active FR3119986B1 (fr) 2021-02-19 2021-02-19 Composition émulsion eau dans huile et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements

Country Status (10)

Country Link
US (1) US20240100045A1 (fr)
EP (1) EP4294364A2 (fr)
JP (1) JP2024507011A (fr)
KR (1) KR20230147155A (fr)
CN (1) CN116887811A (fr)
AU (1) AU2022222303A1 (fr)
CA (1) CA3204646A1 (fr)
FR (1) FR3119986B1 (fr)
WO (1) WO2022175434A2 (fr)
ZA (1) ZA202306742B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4306112A1 (fr) * 2022-07-15 2024-01-17 Tarian Pharma Nouveau regime posologique d'une composition comprenant de la brimonidine pour son utilisation dans la prevention et le traitement des dommages cutanes resultant d'un rayonnement

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2779063A1 (fr) * 2009-10-26 2011-05-05 Galderma Pharma S.A. Procedes de traitement ou de prevention d'un erytheme aigu
ES2618907T3 (es) * 2010-12-03 2017-06-22 Allergan, Inc. Composiciones farmacéuticas en crema que comprenden oximetazolina
MX2016001104A (es) * 2013-07-26 2016-08-12 Galderma Res & Dev Composiciones para tratar engrosamiento de la piel.

Also Published As

Publication number Publication date
WO2022175434A2 (fr) 2022-08-25
US20240100045A1 (en) 2024-03-28
WO2022175434A3 (fr) 2022-10-13
FR3119986A1 (fr) 2022-08-26
KR20230147155A (ko) 2023-10-20
CN116887811A (zh) 2023-10-13
EP4294364A2 (fr) 2023-12-27
ZA202306742B (en) 2024-02-28
CA3204646A1 (fr) 2022-08-25
AU2022222303A1 (en) 2023-09-21
JP2024507011A (ja) 2024-02-15

Similar Documents

Publication Publication Date Title
US11154533B2 (en) Topical compositions and methods for treating inflammatory skin diseases
US11648256B2 (en) Topical compositions and methods for treating psoriasis
EP2482788B1 (fr) Compositions de tétracycline à usage topique
US9968591B2 (en) Antifungal composition
AU2013323766B2 (en) Topical ketoprofen composition
JP7402301B2 (ja) 水混和性の薬学的に許容可能な溶媒の水性ブレンド中のロフルミラストの医薬組成物
Wan et al. Microemulsion based gel for topical dermal delivery of pseudolaric acid B: In vitro and in vivo evaluation
EP3615014B1 (fr) Composition pharmaceutique topique comprenant au moins de l'amitriptyline pour le traitement de douleurs neuropathiques périphériques
US11839656B2 (en) Pharmaceutical formulations containing corticosteroids for topical administration
FR3119986B1 (fr) Composition émulsion eau dans huile et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements
US20180036269A1 (en) Topical Pharmaceutical Formulation
US20230338383A1 (en) Laureth-4 containing topical formulations
FR3119987B1 (fr) Composition hydrogel et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements
EP4196477A1 (fr) Formulations de gel à base d'élastomère anhydre contenant du tofacitinib
Acharya In vitro corneal permeation of etoricoxib from oil drops
WO2022036455A1 (fr) Compositions analgésiques/anti-inflammatoires doubles comprenant des agonistes du récepteur cb2, associations, et leurs méthodes d'utilisation
RU2538680C2 (ru) Фармацевтическая композиция для лечения атопического дерматита и способ ее получения
Zaman M icroemulsion Formulation for Topical Delivery of M iconazole Nitrate
JP2009007265A (ja) 表在性真菌症予防および治療用非経口投与剤
JP2015193623A (ja) 安定化された外用医薬組成物
JP2014152134A (ja) 貯留型医薬組成物

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20220826

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4